Clinical trial
A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
NCT02955888 is registered in ClinicalTrials.gov with Liminal BioSciences Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
- Lead sponsor
- Liminal BioSciences Ltd.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 3, 2017
- Completion date
- February 28, 2018
- Enrollment
- 11 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.